News
ANEB
2.960
+2.07%
0.060
Weekly Report: what happened at ANEB last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at ANEB last week (0415-0419)?
Weekly Report · 04/22 11:38
Weekly Report: what happened at ANEB last week (0408-0412)?
Weekly Report · 04/15 11:29
Weekly Report: what happened at ANEB last week (0401-0405)?
Weekly Report · 04/08 11:33
Weekly Report: what happened at ANEB last week (0325-0329)?
Weekly Report · 04/01 11:30
Weekly Report: what happened at ANEB last week (0318-0322)?
Weekly Report · 03/25 11:34
Weekly Report: what happened at ANEB last week (0311-0315)?
Weekly Report · 03/18 11:32
Weekly Report: what happened at ANEB last week (0304-0308)?
Weekly Report · 03/11 11:28
Weekly Report: what happened at ANEB last week (0226-0301)?
Weekly Report · 03/04 11:32
Weekly Report: what happened at ANEB last week (0219-0223)?
Weekly Report · 02/26 11:46
Weekly Report: what happened at ANEB last week (0212-0216)?
Weekly Report · 02/19 11:49
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
TipRanks · 02/15 19:25
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?
TipRanks · 02/15 06:02
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
Biopharmaceutical company Anebulo Pharmaceuticals reports second quarter financial results. The company's primary focus is on developing therapy for acute cannabinoid intoxication. Company hopes to be the first company to have an approved treatment for the condition. The company reports results for the three months ended Dec. 31.
Benzinga · 02/14 16:37
Anebulo Pharmaceuticals Inc: Quarterly report
Press release · 02/14 14:22
Anebulo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Anebulo Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 11 cents per share. The mean expectation of three analysts was for a loss of 10 cents. The average analyst rating on the shares is "buy"
Reuters · 02/13 22:43
Anebulo Pharmaceuticals GAAP EPS of -$0.11 misses by $0.01
Seeking Alpha · 02/13 22:09
Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Benzinga · 02/13 21:43
*Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Dow Jones · 02/13 21:07
Press Release: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. Is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. The company's lead product candidate, selonabant, has been adopted as the generic name for ANEB-001. The company announced financial results for the three months ended December 31, 2023. Anebula Pharmaceuticals reports second quarter fiscal year 2024 financial results.
Dow Jones · 02/13 21:05
More
Webull provides a variety of real-time ANEB stock news. You can receive the latest news about Anebulo Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.